Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6% Market Closed
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Frontage Holdings Corp
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Long-Term Investments
$10.1m
CAGR 3-Years
178%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Long-Term Investments
$175m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
6%
IQVIA Holdings Inc
NYSE:IQV
Long-Term Investments
$320m
CAGR 3-Years
27%
CAGR 5-Years
17%
CAGR 10-Years
17%
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Long-Term Investments?
Long-Term Investments
10.1m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Long-Term Investments amounts to 10.1m USD.

What is Frontage Holdings Corp's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
0%

Over the last year, the Long-Term Investments growth was 16%. The average annual Long-Term Investments growth rates for Frontage Holdings Corp have been 178% over the past three years .

Back to Top